AXT Q2 Blowout Tests DeepValue's Cautious WAIT Stance

What happened

AXT's Q2 2026 results, released after the DeepValue report's data cutoff, showed revenue soaring 77% sequentially to $47.6 million, record indium phosphide sales, and gross margin expanding to 44.9%, with non-GAAP net income of $11.9 million versus a loss a year ago. This performance far exceeds the master report's bull scenario, which had modeled Q3-Q4 2026 revenue of $36-42 million and gross margin above 35%, indicating that AI-driven InP demand and the Coherent agreement are converting into shipments faster than anticipated. However, the master report's core risks remain unchanged: China export permit unpredictability (North America revenue was only 2% of FY2025), Coherent's parallel internal InP capacity expansion, and a history of working capital absorption with inventory at $90.2 million as of Q1. The Seeking Alpha article argues the valuation is now worth the risk, but the stock had already risen from $2.37 to $49.85 by mid-July, roughly a 20x increase, and post-earnings momentum may have pushed it beyond the master report's trim threshold of $65. While the operating inflection is real, the sustainability of 44.9% gross margin and the durability of external demand against Coherent's vertical integration are not yet proven, and insider selling clusters earlier in 2026 add a cautionary note.

Implication

For long-term investors, the Q2 beat confirms that AXT's capacity expansion and export permit progress are translating into revenue, supporting a fundamental re-rating from cyclical loss-maker to AI-optics compounder. However, the stock's valuation now embeds flawless execution: with a market cap likely above $2.65 billion after the post-earnings surge, the company must sustain gross margins near 45% and continue sequential revenue growth to justify even the bull case. The master report's $70 bull-case implied value assumes Q3-Q4 revenue of $36-42 million and gross margin above 35%, so if Q2 is a one-time spike due to backlog liquidation or favorable mix, the stock could mean-revert sharply. Export permit risk remains binary: any tightening by Chinese authorities (as suggested by Reuters in June 2026) could stall shipments and cause inventory to balloon again, reversing the working capital improvement. Coherent's internal capacity doubling by end-2026 is a structural threat that could reduce AXT's external demand just as its own capacity comes online, making the 2027 demand picture uncertain; therefore, position sizing should reflect a high-risk, high-reward profile rather than a bulletproof growth story.

Thesis delta

The WAIT thesis from the DeepValue report is now challenged by Q2 results that exceeded even the bull scenario, suggesting a shift toward a more constructive view. The core investment case has strengthened: revenue conversion is happening faster than modeled, and gross margins are well above previous assumptions. However, the rating cannot move to BUY until we see at least another quarter of sustained high-margin revenue and clearer export permit visibility, especially for North America, because the stock's recent move likely prices in near-perfect execution.